With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
